What Verantos does

Verantos, Inc. is a privately held health technology company founded in 2013 and headquartered in Menlo Park, California. The company generates high-validity real-world evidence (RWE) for life sciences organizations using a proprietary AI-based deep phenotyping platform that extracts structured and unstructured patient information — including clinical narrative typically absent from coded EHR fields — to produce clinically rich, traceable data sets. Its product portfolio centers on the Verantos Evidence Platform (comprising a federated research network, AI engine, data processing layer, and research analytics), a portfolio of disease-specific Pragmatic Registries across cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, and custom Observational Research services. Data is normalized and delivered in OMOP CDM format, and the company reports access to over 50 million patients across 29 states through partnerships with academic medical centers and community health systems.

Verantos serves primarily top-tier pharmaceutical and biotechnology firms, with named engagements including Amgen and an undisclosed set of top-10 life sciences customers. Secondary customers include healthcare providers and academic medical centers participating in the research network, payers and HTA bodies for market access evidence, and regulatory agencies (notably the FDA, which selected Verantos as a demonstration project for regulatory guidance on data quality). The business model combines subscription-based access to high-validity RWE data and Pragmatic Registry datasets with project-based observational research services, priced on negotiated annual contracts.

The company is led by CEO Dan Riskin and an executive team including President Anand Shroff, VP Engineering, and VP Marketing. To date, disclosed capital inflows are limited to National Science Foundation grants (a $225K award in 2018 and $1.2M in 2020) for RWE outcomes research; broader venture funding history is not disclosed in the input. Verantos has been recognized across multiple years on the Deloitte Technology Fast 500 and Inc. 5000, was named among the Top 50 Healthcare Technology Companies of 2025, and was recognized as a leader among Top AI Healthcare Companies in 2026. Its science has been validated and funded by NIH, NSF, and FDA, distinguishing it credential-wise within the RWE vendor landscape.

Name

Verantos

Legal name

Verantos, Inc.

Website

https://verantos.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Verantos is a private health technology company that uses AI-based deep phenotyping to generate high-validity real-world evidence from structured and unstructured EHR data, serving top-tier pharmaceutical and biotechnology firms with subscription registries and custom observational research.

Ownership category

akta.pro rank

Product category

Real-World Evidence Platform

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

akta.pro secondary industries

Real-World Data (RWD) Platforms & Clinical Data Curation (HLACAIAJ), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

Keywords

• Real-world evidence
• Clinical data analytics
• Pharmaceutical research services
• Health data platform
• EHR phenotyping

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. High-validity RWE Data and Analytics Services: Subscription-based access to high-quality real-world data and evidence generation services for life sciences companies. Services span clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives across therapeutic areas.
2. Pragmatic Registry Subscriptions: Disease-specific registry subscriptions providing indication-specific data sets with configurable variables and endpoints. Registries available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas.
3. Observational Research Studies: Custom observational research generating high-validity RWE for life sciences companies' longitudinal studies with deep phenotyping to support inclusion/exclusion criteria, endpoints, and outcomes.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Core offering

Verantos generates high-validity real-world evidence (RWE) at scale from complete patient records using proprietary AI-based deep phenotyping technology and natural language processing applied to structured and unstructured EHR data. The company offers the Verantos Evidence Platform, disease-specific Pragmatic Registries (cardiovascular, neuroscience, respiratory, gastrointestinal), and Observational Research services to life sciences organizations for clinical development, market access, pharmacovigilance, and regulatory submissions.

Product overview

Verantos is a real-world evidence company offering a platform-plus-products architecture centered on the Verantos Evidence Platform. The platform uses proprietary deep phenotyping technology and AI to generate high-validity RWE from complete patient records including unstructured EHR clinical narrative. The product portfolio includes Pragmatic Registries (disease-specific registries for cardiovascular, neuroscience, respiratory, and gastrointestinal areas), Observational Research services, and access to the Verantos Research Network (federated data network of 50+ million patients across 29 states). Data is normalized and delivered in OMOP CDM format.

Differentiator

Problem solved

Functional benefit

Brands

• Pragmatic Registry: Disease-specific registries of study subjects generated from routinely collected, real-world data, enabling life sciences companies to subscribe to clinically rich, high-quality data sets.
• Verantos Evidence Platform
• Verantos Research Network

Products and services

• Verantos Evidence Platform
• Pragmatic Registry Disease-specific registries of study subjects generated from routinely collected real-world data, providing clinically rich, high-quality data sets representing the patient journey. Available for cardiovascular, neuroscience, respiratory, and gastrointestinal therapeutic areas, with data normalized and delivered in standardized OMOP CDM format. Specific variants include Cardiovascular (heart failure, stroke, pulmonary hypertension), Neuroscience (Alzheimer's, Parkinson's, dementia, depression, schizophrenia, migraine), Respiratory (asthma, COPD, interstitial lung disease, idiopathic pulmonary fibrosis), and Gastrointestinal (ulcerative colitis, Crohn's disease, celiac disease, primary biliary cholangitis).
• Observational Research
• Verantos Research Network

Quantifiable outcome

• 94.1% F1 score in heart failure phenotyping vs 49.0% for traditional structured query approaches
• +5 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• AmgencoreStrategic or Co-development PartnerCollaborative research partner on multiple high-validity RWE studies. Co-authored heart failure phenotyping manuscript published in BMJ Open, migraine RWE publications, and asthma validation studies presented at CHEST 2023. Multiple commercial engagements as validated customer.
• BayercoreStrategic or Co-development PartnerLife sciences partner visible in partner logo section on homepage, indicating collaborative relationship for RWE evidence generation.
• Academic Medical Centers (unnamed)coreStrategic or Co-development PartnerLeading academic medical centers as research partners in the Verantos Research Network, providing access to structured and unstructured EHR data for evidence generation.
• Community Health Systems (unnamed)coreStrategic or Co-development PartnerCommunity health systems as research network partners enabling geographic distribution across 29 states for generalizability and external validity.
• Disease RegistriessupportingTechnology or IntegrationRegistry partners contributing to the federated data network alongside claims aggregators for complete study subject views.
• Food and Drug Administration (FDA)coreStrategic or Co-development PartnerSelected as FDA demonstration project to enable regulatory guidance on data quality. Verantos helped shape policy on use of advanced clinical data and technologies through Congressional testimony on 21st Century Cures Initiative.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Flatiron Health: Flatiron Health provides real-world evidence derived from EHR and oncology data for life sciences, very similar to Verantos' RWE-from-EHR model. Both serve pharma/biotech for clinical development and regulatory evidence, though Flatiron is oncology-specialized and part of Roche.
• Tempus AI: Tempus combines molecular and clinical data with AI to generate real-world evidence for life sciences, including oncology and increasingly other therapeutic areas. Comparable to Verantos in AI-driven RWE for pharma, with broader multi-omic and clinical-trial offerings.
• Aetion: Aetion provides a regulatory-grade real-world evidence platform used by pharma, payers, and regulators including FDA collaborations. Highly comparable to Verantos in targeting regulatory-grade RWE for life sciences decisions.
• TriNetX: TriNetX operates a global federated health-research network providing real-world data and analytics for clinical trial and observational research. Comparable to Verantos' Research Network and observational research offerings, serving pharma across therapeutic areas.

Broad incumbents

• IQVIA (Real-World Solutions): IQVIA offers extensive RWE, HEOR, and real-world data services to life sciences globally. Overlaps with Verantos across observational research, registry, and regulatory-grade RWE, but at vastly greater scale and as part of a broad CRO/data portfolio.
• Optum (UnitedHealth Group): Optum's Life Sciences division delivers real-world data and evidence to pharma, drawing on claims and EHR assets. Competes with Verantos in RWE for clinical development and market access, but as part of a much larger payer/provider data conglomerate.
• Cognizant (RWE / TriZetto): Cognizant's life sciences services include real-world evidence, HEOR, and clinical data analytics through its broader IT services portfolio. Competes indirectly with Verantos for pharma RWE engagements, especially for large enterprise transformations.
• Syneos Health (now part of Elliott/Patient Square): Syneos Health offers real-world evidence and observational research services alongside its CRO operations. Comparable to Verantos in observational RWE delivery, though as part of a full clinical and commercial services portfolio for life sciences.

Emerging players

• Truveta: Truveta aggregates de-identified EHR data from large US health systems to deliver real-world evidence to life sciences. Comparable in using health-system-sourced EHR data for pharma RWE, with a federated member-system model similar to Verantos' Research Network.
• Atropos Health: Atropos Health generates real-world evidence from EHR data using AI to answer clinical and research questions for providers and life sciences. Comparable to Verantos in AI-driven RWE from EHR, but with a broader provider-and-pharma footprint and federated data approach.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/VerantosRWE
• LinkedInlinkedin.com/company/verantos

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verantos